Shares of Prometheus Biosciences, Inc. (NASDAQ:RXDX – Get Rating) have been assigned a consensus recommendation of “Hold” from the eleven ratings firms that are currently covering the company, Marketbeat reports. Seven analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year price […]
Renaissance Capital LLC acquired a new position in shares of Prometheus Biosciences, Inc. (NASDAQ:RXDX – Get Rating) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 11,503 shares of the biopharmaceutical company’s stock, valued at approximately $1,235,000. Prometheus Biosciences comprises […]
Artia Global Partners LP bought a new stake in Prometheus Biosciences, Inc. (NASDAQ:RXDX – Get Rating) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 22,321 shares of the biopharmaceutical company’s stock, valued at approximately $2,455,000. Prometheus Biosciences accounts for […]
Wexford Capital LP purchased a new position in Prometheus Biosciences, Inc. (NASDAQ:RXDX – Get Rating) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 4,506 shares of the biopharmaceutical company’s stock, valued at approximately $496,000. Other hedge funds and other institutional investors also recently made changes […]
Mirae Asset Global Investments Co. Ltd. increased its stake in Prometheus Biosciences, Inc. (NASDAQ:RXDX – Get Rating) by 16.2% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 16,051 shares of the biopharmaceutical company’s stock after acquiring an additional 2,241 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Prometheus […]